These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30785027)

  • 21. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    Boudin L; Gonçalves A; Sabatier R; Moretta J; Sfumato P; Asseeva P; Livon D; Bertucci F; Extra JM; Tarpin C; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Sobol H; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Viens P; Eisinger F; Chabannon C
    Bone Marrow Transplant; 2016 Aug; 51(8):1082-6. PubMed ID: 27042835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
    Zavitsanos PJ; Wazer DE; Hepel JT; Wang Y; Singh K; Leonard KL
    Am J Clin Oncol; 2018 Dec; 41(12):1252-1256. PubMed ID: 29782359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
    Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
    Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
    Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
    JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    Gargiulo P; Pensabene M; Milano M; Arpino G; Giuliano M; Forestieri V; Condello C; Lauria R; De Placido S
    BMC Cancer; 2016 Jul; 16():375. PubMed ID: 27377827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
    Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
    Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
    Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
    Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
    Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
    Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
    Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Boughey JC
    Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
    Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
    Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
    Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.